Research Article

Distribution of hepatitis C virus genotypes in Ordu province

Volume: 16 Number: 1 March 25, 2025
EN TR

Distribution of hepatitis C virus genotypes in Ordu province

Abstract

Aim: Hepatitis C virus (HCV) infection is a major health problem worldwide and leads to chronic liver disease, cirrhosis, and hepatocellular carcinoma. Genotype 1, the most common genotype worldwide, usually requires longer and more complex treatment regimens compared to other genotypes. HCV infection is closely associated with changes in liver enzyme levels, especially alanine aminotransferase (ALT). This study aims to determine the distribution of HCV genotypes in chronic HCV patients and to investigate the relationship between HCV genotype and serum ALT levels. Material and Methods: In this retrospective study, the outcomes of patients diagnosed with chronic liver disease due to HCV at Ordu University Medical Faculty, Education and Research Hospital between May 2021 and October 2023 were analyzed. HCV genotyping was performed using the Bosphore HCV Genotyping Kit v5 (Anatolia Geneworks, Türkiye) according to the manufacturer's instructions. Serum ALT levels were measured using the electrochemiluminescence immunoassay method (Cobas e 601, Roche, Germany). Results: A total of 219 HCV-RNA positive patients were included in the study. Of all patients, 125 (57.1%) were female and 94 (42.9%) were male. When genotype distribution was examined, it was seen that 200 patients (91.3%) had genotype 1b, 9 patients (4.1%) had genotype 1a, 7 patients (3.2%) had genotype 3, 2 patients (0.9%) had genotype 1, and 1 patient (0.5%) had genotype 4. A total of 9 patients had serum ALT levels above 40 IU/L. Conclusion: Genotype 1b remains the most frequently detected genotype among our patients, while the prevalence of Genotype 3 has changed over the years. No significant differences were found in serum ALT levels, mean age, and gender distribution between patients infected with Genotype 1 and other genotypes.

Keywords

Supporting Institution

The authors declared that this study has received no financial support.

Ethical Statement

This study is approved by Ordu University Institution's Clinical Research Ethics Committee (270/10.11.2023).

Thanks

Yok

References

  1. Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol. 2021;45(3):101626.
  2. Ferri S, Muratori L, Lenzi M, Granito A, Bianchi FB, Vergani D. HCV and autoimmunity. Curr Pharm Des. 2008;14(17):1678-85.
  3. Nahon P, Cobat A. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet. Haziran 2020;139(6-7):855-63.
  4. Nutini MFR, Hunter J, Giron L, Pires AFNPC, Kohiyama IM, Camargo M, et al. HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country. PLoS One. 2020;15(1):e0227082.
  5. Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, et al. Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. Virol J. Aralık 2016;13(1):32.
  6. Sakagishi Y. Alanine aminotransferase (ALT). Nihon Rinsho Jpn J Clin Med. 1995;53(5):1146-50.
  7. Kanda T, Matsumoto N, Ishii T, Arima S, Shibuya S, Honda M, et al. Chronic hepatitis C: Acute exacerbation and alanine aminotransferase flare. Viruses. 2023;15(1):183.
  8. Baharlou R, Romani B, Kiani SJ, Sadeghi K, Shadmand E, Fazel H, et al. Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients. Med Microbiol Immunol (Berl). 2018;207(1):65-74.

Details

Primary Language

English

Subjects

Clinical Microbiology

Journal Section

Research Article

Publication Date

March 25, 2025

Submission Date

September 23, 2024

Acceptance Date

January 23, 2025

Published in Issue

Year 2025 Volume: 16 Number: 1

APA
Kalaycı, H. Ö., Çalgın, M. K., Erdal, H., & Gürpınar, A. B. (2025). Distribution of hepatitis C virus genotypes in Ordu province. Turkish Journal of Clinics and Laboratory, 16(1), 1-6. https://doi.org/10.18663/tjcl.1554814
AMA
1.Kalaycı HÖ, Çalgın MK, Erdal H, Gürpınar AB. Distribution of hepatitis C virus genotypes in Ordu province. TJCL. 2025;16(1):1-6. doi:10.18663/tjcl.1554814
Chicago
Kalaycı, Hacer Özlem, Mustafa Kerem Çalgın, Hüseyin Erdal, and Ahmet Burak Gürpınar. 2025. “Distribution of Hepatitis C Virus Genotypes in Ordu Province”. Turkish Journal of Clinics and Laboratory 16 (1): 1-6. https://doi.org/10.18663/tjcl.1554814.
EndNote
Kalaycı HÖ, Çalgın MK, Erdal H, Gürpınar AB (March 1, 2025) Distribution of hepatitis C virus genotypes in Ordu province. Turkish Journal of Clinics and Laboratory 16 1 1–6.
IEEE
[1]H. Ö. Kalaycı, M. K. Çalgın, H. Erdal, and A. B. Gürpınar, “Distribution of hepatitis C virus genotypes in Ordu province”, TJCL, vol. 16, no. 1, pp. 1–6, Mar. 2025, doi: 10.18663/tjcl.1554814.
ISNAD
Kalaycı, Hacer Özlem - Çalgın, Mustafa Kerem - Erdal, Hüseyin - Gürpınar, Ahmet Burak. “Distribution of Hepatitis C Virus Genotypes in Ordu Province”. Turkish Journal of Clinics and Laboratory 16/1 (March 1, 2025): 1-6. https://doi.org/10.18663/tjcl.1554814.
JAMA
1.Kalaycı HÖ, Çalgın MK, Erdal H, Gürpınar AB. Distribution of hepatitis C virus genotypes in Ordu province. TJCL. 2025;16:1–6.
MLA
Kalaycı, Hacer Özlem, et al. “Distribution of Hepatitis C Virus Genotypes in Ordu Province”. Turkish Journal of Clinics and Laboratory, vol. 16, no. 1, Mar. 2025, pp. 1-6, doi:10.18663/tjcl.1554814.
Vancouver
1.Hacer Özlem Kalaycı, Mustafa Kerem Çalgın, Hüseyin Erdal, Ahmet Burak Gürpınar. Distribution of hepatitis C virus genotypes in Ordu province. TJCL. 2025 Mar. 1;16(1):1-6. doi:10.18663/tjcl.1554814